Cue Biopharma, Inc. (CUE): Price and Financial Metrics

Cue Biopharma, Inc. (CUE): $1.50

0.10 (-5.96%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

CUE Price/Volume Stats

Current price $1.50 52-week high $5.12
Prev. close $1.60 52-week low $1.47
Day low $1.47 Volume 212,352
Day high $1.67 Avg. volume 269,172
50-day MA $2.02 Dividend yield N/A
200-day MA $2.62 Market Cap 72.96M

CUE Stock Price Chart Interactive Chart >


Cue Biopharma, Inc. (CUE) Company Bio


Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company’s biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


CUE Latest News Stream


Event/Time News Detail
Loading, please wait...

CUE Latest Social Stream


Loading social stream, please wait...

View Full CUE Social Stream

Latest CUE News From Around the Web

Below are the latest news stories about CUE BIOPHARMA INC that investors may wish to consider to help them evaluate CUE as an investment opportunity.

CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023

CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.

InvestorPlace Earnings on InvestorPlace | December 14, 2023

Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?

Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.

Yahoo | December 7, 2023

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023. During the fireside chat, Cue Biopharma will discuss recent data highlights from its lead clinical programs, CUE-101 and CUE-102, r

Yahoo | November 22, 2023

Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this call is […]

Yahoo | November 12, 2023

Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, provided a business and financial update for the third quarter of 2023. Recent Business Highlights Presented positive data from ongoing Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting (SITC 2023) held November 1-5. Update

Yahoo | November 9, 2023

Read More 'CUE' Stories Here

CUE Price Returns

1-mo -27.54%
3-mo -50.00%
6-mo -19.79%
1-year -55.88%
3-year -88.32%
5-year -82.44%
YTD -43.18%
2023 -7.37%
2022 -74.80%
2021 -9.59%
2020 -21.20%
2019 237.77%

Continue Researching CUE

Here are a few links from around the web to help you further your research on Cue Biopharma Inc's stock as an investment opportunity:

Cue Biopharma Inc (CUE) Stock Price | Nasdaq
Cue Biopharma Inc (CUE) Stock Quote, History and News - Yahoo Finance
Cue Biopharma Inc (CUE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!